Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
companyunderground
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» This Could Be the Catalyst That Sends Summit Therapeutics' Stock Higher This Year
This Could Be the Catalyst That Sends Summit Therapeutics' Stock Higher This Year
This Could Be the Catalyst That Sends Summit Therapeutics' Stock Higher This Year
Submitted by
admin
on March 13, 2025 - 11:32am
Source:
Motley Fool
News Tags:
Summit Therapeutics
ivonescimab
cancer
non-small cell lung cancer
Headline:
This Could Be the Catalyst That Sends Summit Therapeutics' Stock Higher This Year
snippet:
Summit Therapeutics stock is off to a slow start in 2025, but it still trades at a massive $13 billion valuation.
The biotech doesn't yet generate consistent revenue, but much hope surrounds its cancer drug candidate.
More trials are coming, and if the drug continues to show promise, the stock could start to rally again.
Do Not Allow Advertisers to Use My Personal information
